good point regarding the ability to increase the number of patients treated just based on the shorter duration of therapy and improved tolerability.
I too think the most money to be made will be in the first couple years or so, but I'm not sure I understand why you don't think the large undiagnosed HCV population in this country won't provide a meaningful commercial opportunity for a good number of years to come. Even if you treated all known affected HCV pts in 2 years, there are another 2+ million in the US that will gradually be diagnosed over the next decade plus, many of whom will get treatment
Market Data 
Markets 
AI
